Clinical trials: Lung Cancer Patient
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ovarian, Breast
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and…
- Conditions
- Ovarian, Breast, SCLC, Gastric Cancers
- Trial name
- MEDIOLA (NCT02734004)
- Testing
- Olaparib, MEDI4736, Bevacizumab
- Where
- 47 sites in United States, France and 5 more
- Volunteers
- 264 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Small Cell
BI 2536 Second Line Monotherapy in SCLC
Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.
- Trial name
- NCT00412880
- Testing
- BI 2536
- Where
- 10 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-Small Cell Lung Cancer
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
- Trial name
- NCT02584634
- Testing
- Avelumab, PF-06463922, Crizotinib
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Pfizer
Non-Melanoma Skin Carcinoma
Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung…
- Trial name
- NCT01480219
- Testing
- voriconazole (Vfend), no voriconazole (Vfend)
- Volunteers
- 467 people
- Sponsor
- Pfizer
Lung Cancer, Non-Small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
- Trial name
- CheckMate870 (NCT03195491)
- Testing
- Nivolumab
- Where
- 30 sites in China, Thailand
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Non-Small Cell
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer.
- Trial name
- PEARL (NCT01853878)
- Testing
- Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
- Where
- 39 sites in United States, Estonia and 7 more
- Volunteers
- 137 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small…
- Trial name
- ASTRIS (NCT02474355)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 201 sites in Argentina, Australia and 14 more
- Volunteers
- 3,017 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
This is a phase 2 study. The goal of this study is to find out what effects, good and/or bad, taking erlotinib and ruxolitinib has on the patients and on lung cancer.
- Trial name
- NCT02155465
- Testing
- Ruxolitinib, Erlotinib
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small…
- Trial name
- NCT03563716
- Testing
- Atezolizumab, Tiragolumab
- Where
- 40 sites in United States, France and 4 more
- Volunteers
- 135 people
- Sponsor
- Genentech, Inc.
Gynecologic Cancer, Colorectal Cancer
Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity
The purpose of this study is to incorporate feedback from cancer patients and providers to adapt, implement, and test an intervention.
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04314284
- Testing
- I Can PIC, Historical control survey, Post-intervention survey (I Can PIC participants)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Washington University School of Medicine